Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aplastic anemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Aplastic anemia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-001257-22 Sponsor Protocol Number: 20210112 Start Date*: 2023-03-29
    Sponsor Name:Amgen, Inc.
    Full Title: Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Non Asian Adult Severe Aplastic Anemia (SAA) Subjects who are Either Previously Untreated With Immunosuppressive T...
    Medical condition: Aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    20.1 10005329 - Blood and lymphatic system disorders 10002968 Aplastic anaemia, unspecified LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083893 Acquired aplastic anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10032510 Other specified aplastic anaemias LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002969 Aplastic anemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002037 Anaemia aplastic LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000902-55 Sponsor Protocol Number: RATGAA07 Start Date*: 2007-09-19
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: Prospective Phase II study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patie...
    Medical condition: Acquired severe aplastic anaemia and transfusion dependent non-severe aplastic anaemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10002274 Anemia aplastic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000363-40 Sponsor Protocol Number: 8409032 Start Date*: 2016-01-07
    Sponsor Name:European Society for Blood and Marrow Transplantation
    Full Title: A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients.
    Medical condition: Idiopathic (Severe) Aplastic Anemia, a bone marrow failure syndrome which results in the normal hematopoietic tissue completely missing from the bone marrow, accounting for the subsequent pancytope...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001151-22 Sponsor Protocol Number: Alesaa Start Date*: 2007-06-06
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS.
    Medical condition: Aplastic anemia and single-lineage bone marrow failure
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10002965 Aplasia pure red cell PT
    13.1 10005329 - Blood and lymphatic system disorders 10047350 Very few granulocyte precursors LLT
    13.1 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    13.1 10005329 - Blood and lymphatic system disorders 10001507 Agranulocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002814-29 Sponsor Protocol Number: CETB115E2403 Start Date*: 2017-03-21
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired...
    Medical condition: First-line severe aplastic anaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) NL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002155-11 Sponsor Protocol Number: B5411003 Start Date*: 2021-06-09
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE A...
    Medical condition: Moderate and above aplastic anemia
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003166-91 Sponsor Protocol Number: CETB115E2201 Start Date*: 2019-05-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, rela...
    Medical condition: Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001223-31 Sponsor Protocol Number: KAISII Start Date*: 2016-10-11
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis
    Medical condition: Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038271 Refractory anaemia with excess blasts in transformation LLT
    19.0 10042613 - Surgical and medical procedures 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    19.0 10042613 - Surgical and medical procedures 10067862 Allogeneic stem cell transplantation LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    19.0 10005329 - Blood and lymphatic system disorders 10010776 Constitutional aplastic anaemia LLT
    19.0 10005329 - Blood and lymphatic system disorders 10068063 Aplastic anaemia relapse LLT
    19.0 10005329 - Blood and lymphatic system disorders 10036699 Primary idiopathic aplastic anaemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    19.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000884 Acute myeloid leukaemia NOS LLT
    19.0 10005329 - Blood and lymphatic system disorders 10032510 Other specified aplastic anaemias LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066355 Treatment related acute myeloid leukaemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060355 Acute myeloid leukaemia in remission LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066764 Acute myeloid leukaemia progression LLT
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000174-19 Sponsor Protocol Number: 9345 Start Date*: 2015-01-27
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Re...
    Medical condition: Moderate Aplastic Anemia (MAA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002031-29 Sponsor Protocol Number: R7257-RAA-1947 Start Date*: 2020-11-05
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ...
    Medical condition: SEVERE APLASTIC ANEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004364-35 Sponsor Protocol Number: CETB115AUS01T Start Date*: 2018-07-25
    Sponsor Name:National Heart, Lung, and Blood
    Full Title: Eltrombopag added to standard immunosuppression in treatment-naïve severe aplastic anemia.
    Medical condition: Severe aplastic anemia (SAA)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-001546-25 Sponsor Protocol Number: NL48960.029.14 Start Date*: 2015-01-06
    Sponsor Name:VU University Medical Center
    Full Title: Short versus extended antibiotic treatment with a carbapenem for high-risk febrile neutropenia in hematology patients with Fever of Unknown Origin: a randomized multicenter open-label non-inferiori...
    Medical condition: Febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    19.1 10005329 - Blood and lymphatic system disorders 10002969 Aplastic anemia LLT
    19.1 10021881 - Infections and infestations 10003999 Bacteremia LLT
    19.1 10021881 - Infections and infestations 10007810 Catheter related infection LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028566 Myeloma LLT
    19.1 10021881 - Infections and infestations 10062957 Catheter bacteraemia LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    19.1 10021881 - Infections and infestations 10056520 Catheter site infection PT
    19.1 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012746-23 Sponsor Protocol Number: JS001 Start Date*: 2009-05-12
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept
    Medical condition: acquired aplastic anemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001657-26 Sponsor Protocol Number: KCH-BMT-07-1.0 Start Date*: 2008-02-29
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Single Centre Phase II Pilot study of Unrelated Cord Blood Transplantation in Patients with Poor Risk Haematological Malignancies.
    Medical condition: 1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic transplantation is considered as the best treatment option. 2. Acute lymphoblastic leukaemia (ALL) 3. Non-Hodgkin’s l...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10009013 Chronic myeloid leukaemia LLT
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    9.1 10020328 Hodgkin's lymphoma LLT
    9.1 10029593 Non-Hodgkin's lymphoma NOS LLT
    9.1 10003892 B-cell chronic lymphocytic leukaemia/prolymphocytic leukaemia/small lymphocytic lymphoma LLT
    9.1 10002968 Aplastic anaemia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004914-18 Sponsor Protocol Number: CD-001 Start Date*: 2005-01-21
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: A pilot multicentric study for the use of the anti-TNF alfa in patients with: 1) Fanconi Anemia with marrow failure with no bone marrow compatible donor 2) In patients with acquired aplastic anem...
    Medical condition: Marrow failure in patients refractary/non eligible to conventional treatments
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002935-88 Sponsor Protocol Number: VX18-CTX001-131 Start Date*: 2019-03-13
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)
    Medical condition: Transfusion-dependent β thalassemia (TDT). Severe sickle cell disease (SCD).
    Disease: Version SOC Term Classification Code Term Level
    26.1 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) FR (Ongoing) GR (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003226-16 Sponsor Protocol Number: BP-404 Start Date*: 2017-02-03
    Sponsor Name:Bellicum Pharmaceuticals, Inc.
    Full Title: Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders
    Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000393-76 Sponsor Protocol Number: ZKI-SCT-HAPLO-0106 Start Date*: 2006-10-25
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt am Main
    Full Title: Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases.
    Medical condition: Pediatric patients with malignant and non-malignant high-risk diseases, where the allogeneic stem cell transplantation represents the only option for a curative therapy and where an adequate HLA-id...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005030-54 Sponsor Protocol Number: MK-0991-042 Start Date*: 2015-02-24
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 2...
    Medical condition: Neutropenic immunosuppressed
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003435-11 Sponsor Protocol Number: VL2397-201 Start Date*: 2018-08-14
    Sponsor Name:Vical Incorporated
    Full Title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Immunocompromised Adults
    Medical condition: Invasive Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10051597 Cerebral aspergillosis PT
    20.1 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 10021881 - Infections and infestations 10003490 Aspergillosis pharyngeal LLT
    20.1 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    20.0 10021881 - Infections and infestations 10059259 Pulmonary aspergillosis LLT
    20.0 10021881 - Infections and infestations 10003488 Aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:22:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA